Perspective Therapeutics (NYSEAMERICAN:CATX) Posts Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) released its quarterly earnings data on Monday. The company reported ($0.51) earnings per share (EPS) for the quarter, FiscalAI reports. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. The firm had revenue of $0.04 million for the quarter.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $5.22 on Tuesday. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.16. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $4.22 and a two-hundred day moving average price of $3.41.

Analysts Set New Price Targets

A number of research firms have commented on CATX. B. Riley Financial dropped their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. UBS Group restated a “buy” rating and issued a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Friday, January 30th. Truist Financial began coverage on shares of Perspective Therapeutics in a research note on Monday, November 24th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright raised their price target on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics has a consensus rating of “Buy” and an average price target of $12.38.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Aigen Investment Management LP bought a new stake in Perspective Therapeutics during the fourth quarter worth approximately $28,000. Russell Investments Group Ltd. boosted its holdings in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after purchasing an additional 5,475 shares during the period. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at approximately $31,000. AXQ Capital LP raised its position in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $35,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.